851784-76-4

Usage

Uses

Used in Pharmaceutical Industry:
Zolpidem is used as a sleep aid for the treatment of insomnia and other sleep disorders. It is effective in inducing sleep by slowing down the brain's activity, providing relief to individuals with sleep disturbances.
Used in Medical Treatments:
As a sedative-hypnotic, Zolpidem is utilized in medical treatments to manage sleep disorders, helping patients achieve a restful and uninterrupted sleep. It is crucial to follow the prescribed dosages and usage instructions to minimize the risk of dependency and side effects.

Upstream product

• 50-00-0 formaldehyd 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 876108-97-3 C₉H₉Cl₂NO 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 1609545-55-2 C₉H₉Cl₂NO*C₇H₈O₃S 
• 14446-24-3 6-hydroxy-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 851784-80-0 2-(tert-butyl) 6-methyl 5,7-dichloro-3,4-dihydroisoquinoline-2,6(1Η)-dicarboxylate 
• 851784-82-2 2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 851784-78-6 C₁₅H₁₆Cl₂F₃NO₅S 

Relevant academic research and scientific papers

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST

The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

This letter describes the discovery of a novel series of tetrahydroisoquinoline (THIQ)-derived small molecules that potently inhibit both human T-cell migration and super-antigen induced T-cell activation through disruption of the binding of integrin LFA-1 to its receptor, ICAM-1. In addition to excellent in vitro potency, 6q shows good pharmacokinetic properties and its ethyl ester (6t) demonstrates good oral bioavailability in both mouse and rat. Either intravenous administration of 6q or oral administration of its ethyl ester (6t) produced a significant reduction of neutrophil migration in a thioglycollate-induced murine peritonitis model.